Targeting cytokines in inflammatory bowel disease.

Neurath M (2022)

Publication Type: Journal article, Review article

Publication year: 2022

Journal

Science Translational Medicine American Association for the Advancement of Science

Book Volume: 14

Journal Issue: 675

DOI: 10.1126/scitranslmed.abq4473

Abstract

Targeting cytokines in inflammatory bowel disease (IBD) is a useful clinical approach. Potential therapies for IBD include regulatory T cell transfer to restore cytokine balance, blocking proinflammatory cytokines (e.g., IL-12 and IL-23) or their receptors (sIL-6R and IL-36R), or inhibiting signaling kinases (e.g., JAK). An emerging trend in IBD therapy is to combine several anti-cytokine agents simultaneously.

Authors with CRIS profile

Markus Neurath Lehrstuhl für Innere Medizin I

How to cite

APA:

Neurath, M. (2022). Targeting cytokines in inflammatory bowel disease. Science Translational Medicine, 14(675). https://doi.org/10.1126/scitranslmed.abq4473

MLA:

Neurath, Markus. "Targeting cytokines in inflammatory bowel disease." Science Translational Medicine 14.675 (2022).

BibTeX: Download